title: Inhibitory effect of endostar on specific angiogenesis induced by human hepatocellular carcinoma.
abstract: To investigate the effect of endostar on specific angiogenesis induced by human hepatocellular carcinoma, this research systematically elucidated the inhibitory effect on HepG2-induced angiogenesis by endostar from 50 ng/mL to 50000 ng/mL. We employed fluorescence quantitative Boyden chamber analysis, wound-healing assay, flow cytometry examination using a coculture system, quantitative analysis of tube formation, and in vivo Matrigel plug assay induced by HCC conditioned media (HCM) and HepG2 compared with normal hepatocyte conditioned media (NCM) and L02. Then, we found that endostar as a tumor angiogenesis inhibitor could potently inhibit human umbilical vein endothelial cell (HUVEC) migration in response to HCM after four- to six-hour action, inhibit HCM-induced HUVEC migration to the lesion part in a dose-dependent manner between 50 ng/mL and 5000 ng/mL at 24 hours, and reduce HUVEC proliferation in a dose-dependent fashion. Endostar inhibited HepG2-induced tube formation of HUVECs which peaked at 50 ng/mL. In vivo Matrigel plug formation was also significantly reduced by endostar in HepG2 inducing system rather than in L02 inducing system. It could be concluded that, at cell level, endostar inhibited the angiogenesis-related biological behaviors of HUVEC in response to HCC, including migration, adhesion proliferation, and tube formation. At animal level, endostar inhibited the angiogenesis in response to HCC in Matrigel matrix.
authors.affiliation: Postdoctoral Station of Nanjing General Hospital, Nanjing 210002, China ; PLA Cancer Center in Eighty-One Hospital of People's Liberation Army, Nanjing 210002, China ; Department of Pathology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Ye
authors.affiliation: Postdoctoral Station of Nanjing General Hospital, Nanjing 210002, China ; PLA Cancer Center in Eighty-One Hospital of People's Liberation Army, Nanjing 210002, China.
authors.forename: Shukui
authors.initials: S
authors.lastname: Qin
authors.affiliation: Department of Pathology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.
authors.forename: Yanhong
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Postdoctoral Station of Nanjing General Hospital, Nanjing 210002, China ; PLA Cancer Center in Eighty-One Hospital of People's Liberation Army, Nanjing 210002, China.
authors.forename: Jundong
authors.initials: J
authors.lastname: Feng
authors.affiliation: PLA Cancer Center in Eighty-One Hospital of People's Liberation Army, Nanjing 210002, China.
authors.forename: Qiong
authors.initials: Q
authors.lastname: Wu
authors.affiliation: PLA Cancer Center in Eighty-One Hospital of People's Liberation Army, Nanjing 210002, China.
authors.forename: Wenshu
authors.initials: W
authors.lastname: Qu
authors.affiliation: Jiangsu Harbinger Drug Development Co., Ltd., Nanjing 210002, China.
authors.forename: Xiaojin
authors.initials: X
authors.lastname: Yin